Table 3.
Correlation between TMB and clinicopathological parameters (p-value).
| Clinical characteristics | TMB threshold: 59/MB | TMB threshold: 79/MB | ||||
|---|---|---|---|---|---|---|
| Low group (0–59/MB) | High group (>59/MB) | p-value | Low group (0–79/MB) | High group (>79/MB) | p-value | |
| Age | ||||||
| ≤52 | 2 | 6 | 1 | 4 | 4 | 1 |
| >53 | 3 | 5 | 4 | 4 | ||
| Liver cirrhosis | ||||||
| Yes | 4 | 8 | 0.401 | 7 | 5 | 0.713 |
| No | 1 | 1 | 1 | 1 | ||
| Tumor size | ||||||
| <8 cm | 3 | 6 | 0.604 | 5 | 4 | 0.608 |
| ≥8 cm | 1 | 5 | 2 | 4 | ||
| Tumor stage | ||||||
| I, II stage | 1 | 4 | 1 | 2 | 3 | 1 |
| III, IV stage | 4 | 7 | 6 | 5 | ||
| KPS | ||||||
| <100 | 3 | 4 | 0.596 | 4 | 3 | 1 |
| =100 | 2 | 7 | 4 | 5 | ||
| AFP | 5 | 11 | 0.002** | 8 | 8 | 0.001** |
TMB, tumor mutational burden; KPS, Karnofsky Performance Score; AFP, alpha fetoprotein.
**p < 0.001.